

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 (Cancelled).

4. (Currently Amended) A method comprising transplantation of insulin producing cells in the form of individually isolated islets to a patient suffering from insulin dependent diabetes mellitus (IDDM), wherein said individually isolated islets are modified by irreversible adsorption with a clotting inhibiting agent comprising heparin or a fraction or derivative thereof onto the surfaces of the islets,

wherein said individual islet cells are each separately coated with heparin or a fraction or derivative thereof by preincubation of islets in a an aqueous solution containing heparin or a fraction or derivative thereof,

wherein said clotting inhibiting agent acts to inhibit clotting or reduce clotting.

Claims 5-7 (Cancelled).

8. (Previously Presented) The method according to claim 4, wherein more than one clotting inhibiting agent is used.

9. (Previously Presented) The method according to claims 4, wherein the clotting inhibiting agent is supplemented by an inhibitor of complement.

Claim 10 (Cancelled).

11. (Previously Presented) A method for increasing survival of islet cells according to claim 14, in connection with transplantation of insulin producing cells to patients with insulin dependent diabetes mellitus (IDDM), comprising inhibiting of clotting, monitored as reduced generation of thrombin-antithrombin complex (TAT complex).

Claims 12-13 (Cancelled).

14. (Withdrawn) Isolated islets comprising insulin producing cells, wherein the islets are individually coated with a clotting inhibiting agent on the islet surface.

Claims 15-25 (Cancelled)

26. (Withdrawn) A method of using the isolated islets of claim 14, comprising

injecting said islets individually coated with a clotting inhibiting agent into the bloodstream of a patient suffering from insulin dependent diabetes mellitus (IDDM).

27. (New) A method comprising transplantation of insulin producing cells in the form of isolated islets to a patient suffering from insulin dependent diabetes mellitus (IDDM),

wherein said isolated islets are modified by irreversible adsorption of a clotting inhibiting agent comprising heparin or a fraction or derivative thereon onto the surface of the islets;

said modification comprising incubating said islets in a solution of heparin or a fraction of derivative thereof;

wherein said clotting inhibiting agent acts to inhibit or reduce clotting.